002940 昂利康
已收盘 01-14 15:00:00
资讯
新帖
简况
异动快报：昂利康（002940）1月12日14点20分触及涨停板
证券之星 · 01-12 14:25
异动快报：昂利康（002940）1月12日14点20分触及涨停板
每周股票复盘：昂利康（002940）募投项目延期至2026年6月
证券之星 · 01-03
每周股票复盘：昂利康（002940）募投项目延期至2026年6月
昂利康（002940）披露2025年第三次临时股东会决议公告，12月16日股价上涨1.37%
证券之星 · 2025-12-16
昂利康（002940）披露2025年第三次临时股东会决议公告，12月16日股价上涨1.37%
昂利康：将研发作为核心发展动力
证券之星 · 2025-12-16
昂利康：将研发作为核心发展动力
12月15日昂利康创60日新低，富国天盛灵活配置基金基金重仓该股
证券之星 · 2025-12-15
12月15日昂利康创60日新低，富国天盛灵活配置基金基金重仓该股
昂利康（002940）披露获得药品注册证书及药品补充申请批准通知书，12月12日股价下跌6.63%
证券之星 · 2025-12-12
昂利康（002940）披露获得药品注册证书及药品补充申请批准通知书，12月12日股价下跌6.63%
12月12日昂利康跌6.63%，富国天盛灵活配置基金基金重仓该股
证券之星 · 2025-12-12
12月12日昂利康跌6.63%，富国天盛灵活配置基金基金重仓该股
昂利康11.6亿定增押注创新药，毛利率持续滑坡下寻求转型突围
证券之星 · 2025-12-11
昂利康11.6亿定增押注创新药，毛利率持续滑坡下寻求转型突围
昂利康（002940）披露获得药品注册证书，11月28日股价上涨0.4%
证券之星 · 2025-11-28
昂利康（002940）披露获得药品注册证书，11月28日股价上涨0.4%
昂利康最新公告：子公司获得硫糖铝片兽药产品批准文号
证券之星 · 2025-11-28
昂利康最新公告：子公司获得硫糖铝片兽药产品批准文号
昂利康(002940.SZ)取得恩格列净二甲双胍缓释片(II)药品注册证书
智通财经 · 2025-11-28
昂利康(002940.SZ)取得恩格列净二甲双胍缓释片(II)药品注册证书
昂利康11.6亿元定增透视：毛利率腰斩下的创新药豪赌
新浪证券 · 2025-11-27
昂利康11.6亿元定增透视：毛利率腰斩下的创新药豪赌
昂利康：股东可现场查阅股东名册信息
证券之星 · 2025-11-26
昂利康：股东可现场查阅股东名册信息
昂利康最新公告：拟定增募资不超过11.6亿元
证券之星 · 2025-11-25
昂利康最新公告：拟定增募资不超过11.6亿元
昂利康药业计划通过A股定增筹集12亿元以支持项目
美股速递 · 2025-11-25
昂利康药业计划通过A股定增筹集12亿元以支持项目
昂利康（002940）披露2025年第二次临时股东大会决议公告，11月24日股价上涨1.8%
证券之星 · 2025-11-24
昂利康（002940）披露2025年第二次临时股东大会决议公告，11月24日股价上涨1.8%
昂利康(002940.SZ)：化学原料药布比卡因上市申请获批准
智通财经 · 2025-11-17
昂利康(002940.SZ)：化学原料药布比卡因上市申请获批准
11月17日昂利康跌7.60%，富国天盛灵活配置基金基金重仓该股
证券之星 · 2025-11-17
11月17日昂利康跌7.60%，富国天盛灵活配置基金基金重仓该股
11月14日昂利康涨5.52%，富国天盛灵活配置基金基金重仓该股
证券之星 · 2025-11-14
11月14日昂利康涨5.52%，富国天盛灵活配置基金基金重仓该股
昂利康(002940.SZ)：多索茶碱片通过仿制药一致性评价
智通财经 · 2025-11-11
昂利康(002940.SZ)：多索茶碱片通过仿制药一致性评价
加载更多
公司概况
公司名称：
浙江昂利康制药股份有限公司
所属行业：
医药制造业
上市日期：
2018-10-23
主营业务：
浙江昂利康制药股份有限公司的主营业务是从事化学原料药及制剂的研发、生产和销售。公司的主要产品是化学原料药及制剂。
发行价格：
23.07
{"stockData":{"symbol":"002940","market":"SZ","secType":"STK","nameCN":"昂利康","latestPrice":36.48,"timestamp":1768374189000,"preClose":36.93,"halted":0,"volume":13900131,"delay":0,"changeRate":-0.0122,"floatShares":185000000,"shares":202000000,"eps":0.5359,"marketStatus":"已收盘","change":-0.45,"latestTime":"01-14 15:00:00","open":36.98,"high":37.72,"low":35.94,"amount":513000000,"amplitude":0.0482,"askPrice":36.5,"askSize":53,"bidPrice":36.48,"bidSize":371,"shortable":0,"etf":0,"ttmEps":0.5359,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":36.93,"symbolType":"stock","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":40.62,"lowLimit":33.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":201728186,"isCdr":false,"pbRate":4.67,"roa":"--","peRate":68.072402,"roe":"4.99%","epsLYR":0.4,"committee":0.766507,"marketValue":7359000000,"turnoverRate":0.075,"status":1,"floatMarketCap":6759000000},"requestUrl":"/m/hq/s/002940","defaultTab":"news","newsList":[{"id":"2602595029","title":"异动快报：昂利康（002940）1月12日14点20分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2602595029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602595029?lang=zh_cn&edition=full","pubTime":"2026-01-12 14:25","pubTimestamp":1768199123,"startTime":"0","endTime":"0","summary":"证券之星1月12日盘中消息，14点20分昂利康触及涨停板。其所属行业化学制药目前上涨。领涨股为向日葵。该股为宠物经济，合成生物，化学原料药概念热股，当日宠物经济概念上涨1.54%，合成生物概念上涨1.17%，化学原料药概念上涨0.67%。1月9日的资金流向数据方面，主力资金净流出127.6万元，占总成交额0.37%，游资资金净流出256.34万元，占总成交额0.74%，散户资金净流入383.94万元，占总成交额1.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200013979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2600062294","title":"每周股票复盘：昂利康（002940）募投项目延期至2026年6月","url":"https://stock-news.laohu8.com/highlight/detail?id=2600062294","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600062294?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:18","pubTimestamp":1767377894,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，昂利康报收于33.52元，较上周的33.82元下跌0.89%。本周，昂利康12月29日盘中最高价报34.0元。关于募集资金投资项目之杭州药物研发平台项目延期的公告浙江昂利康制药股份有限公司于2025年12月30日召开董事会，审议通过杭州药物研发平台项目延期议案，将项目达到预定可使用状态日期由2025年12月延至2026年6月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2591980975","title":"昂利康（002940）披露2025年第三次临时股东会决议公告，12月16日股价上涨1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591980975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591980975?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:11","pubTimestamp":1765894302,"startTime":"0","endTime":"0","summary":"截至2025年12月16日收盘，昂利康报收于33.41元，较前一交易日上涨1.37%，最新总市值为67.4亿元。该股当日开盘32.78元，最高33.96元，最低32.25元，成交额达3.55亿元，换手率为5.8%。近日，浙江昂利康制药股份有限公司召开2025年第三次临时股东会，会议审议通过了关于公司符合向特定对象发行A股股票条件、2025年度向特定对象发行A股股票方案、发行预案、募集资金使用可行性分析、前次募集资金使用情况、股东回报规划等九项议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600040533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2591672245","title":"昂利康：将研发作为核心发展动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591672245?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:37","pubTimestamp":1765856220,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康(002940)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司的核心竞争力是什么？昂利康回复：您好，目前国内医药生产企业众多，竞争较为激烈，公司始终坚持将研发作为企业的核心发展动力，注重业内合作，立足于开发具有临床价值的优质产品。详情可参考公司各年年度报告“第三节 管理层讨论与分析”，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600015370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2591615658","title":"12月15日昂利康创60日新低，富国天盛灵活配置基金基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615658?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:37","pubTimestamp":1765784256,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日昂利康创60日新低，收盘报32.96元，当日跌3.68%，换手率5.06%，成交量9.38万手，成交额3.14亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为富国基金的富国天盛灵活配置基金。富国天盛灵活配置基金目前规模为6.7亿元，最新净值1.322，较上一交易日下跌0.9%，近一年上涨34.62%。该公募基金现任基金经理为肖威兵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500013035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2590504230","title":"昂利康（002940）披露获得药品注册证书及药品补充申请批准通知书，12月12日股价下跌6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504230?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:05","pubTimestamp":1765548345,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，昂利康报收于34.22元，较前一交易日下跌6.63%，最新总市值为69.03亿元。公司近日发布公告称，浙江昂利康制药股份有限公司近日收到国家药监局签发的双氯芬酸钠肠溶片《药品注册证书》和沙库巴曲缬沙坦钠片《药品补充申请批准通知书》。双氯芬酸钠肠溶片获批规格为25mg，注册分类为化学药品4类，视同通过一致性评价。沙库巴曲缬沙坦钠片获批增加100mg规格，此前已有200mg规格获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2590750745","title":"12月12日昂利康跌6.63%，富国天盛灵活配置基金基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590750745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590750745?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:39","pubTimestamp":1765525180,"startTime":"0","endTime":"0","summary":"证券之星消息，12月12日昂利康跌6.63%创60日新低，收盘报34.22元，换手率8.42%，成交量15.6万手，成交额5.38亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为富国基金的富国天盛灵活配置基金。富国天盛灵活配置基金目前规模为6.7亿元，最新净值1.334，较上一交易日上涨0.0%，近一年上涨36.82%。该公募基金现任基金经理为肖威兵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200018748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2590568565","title":"昂利康11.6亿定增押注创新药，毛利率持续滑坡下寻求转型突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590568565?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:14","pubTimestamp":1765419273,"startTime":"0","endTime":"0","summary":"未来，昂利康能否凭借差异化优势在创新药中成功突围，将直接决定其长远成长空间。战略转向落子创新药，11.6亿元押注肿瘤领域核心管线根据昂利康披露的定增预案，此次募集的11.6亿元将全额投入创新药研发及产业相关项目，精准聚焦肿瘤疾病领域的创新突破。此次将全部募资集中投向创新药领域，清晰彰显了昂利康战略重心的彻底转移。回顾发展历程，昂利康的创新药转型并非一蹴而就。因此，昂利康这场规模达11.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025121100009629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","159992","06978","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2586386297","title":"昂利康（002940）披露获得药品注册证书，11月28日股价上涨0.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586386297","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586386297?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:13","pubTimestamp":1764339186,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，昂利康报收于37.65元，较前一交易日上涨0.4%，最新总市值为75.95亿元。公司近日发布公告称，浙江昂利康制药股份有限公司近日收到国家药品监督管理局签发的恩格列净二甲双胍缓释片药品注册证书，批准文号为国药准字H20256037，有效期至2030年11月24日。该药品为恩格列净和盐酸二甲双胍的复方制剂，适用于2型糖尿病成人患者血糖控制。公司于2024年6月提交上市申请并获受理，此次获批视同通过一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2586788055","title":"昂利康最新公告：子公司获得硫糖铝片兽药产品批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2586788055","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586788055?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:46","pubTimestamp":1764323174,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，公司子公司浙江昂利康动保科技有限公司收到农业农村部核准签发的“硫糖铝片”兽药产品批准文号批件，该兽药具备生产上市销售条件，可进一步丰富公司产品品类，对推动宠物用药战略布局、促进公司发展具有积极意义。但需注意兽药产品上市销售受政策、市场等因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800026183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2586788899","title":"昂利康(002940.SZ)取得恩格列净二甲双胍缓释片(II)药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586788899","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586788899?lang=zh_cn&edition=full","pubTime":"2025-11-28 17:33","pubTimestamp":1764322382,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的恩格列净二甲双胍缓释片(II)《药品注册证书》。恩格列净二甲双胍缓释片(II)是恩格列净和盐酸二甲双胍的复方制剂，适用于正在接受恩格列净和盐酸二甲双胍治疗的2型糖尿病成人患者，用于改善这些患者的血糖控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)取得恩格列净二甲双胍缓释片(II)药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2586924891","title":"昂利康11.6亿元定增透视：毛利率腰斩下的创新药豪赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2586924891","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586924891?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:37","pubTimestamp":1764232620,"startTime":"0","endTime":"0","summary":"昂利康11月26日披露的2025年度向特定对象发行A股股票预案显示，公司拟向特定对象发行A股股票募集资金11.6亿元，用于“创新药研发及产业化项目”等项目。 昂利康于2001年改制成立，总部位于浙江省嵊州市，是一家集医药中间体、原料药和药物制剂为一体，以心血管类、口服头孢类、肾病类、麻醉镇痛类药品为特色的现代化制药企业。昂利康的困境正源于此——2021年64.7%的毛利率如断线风筝般坠落，至2025年前三季度仅剩38.78%，创下近十年新低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-27/doc-infyvtha0104216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","002940","BK0239","BK1161","06978"],"gpt_icon":0},{"id":"2586236767","title":"昂利康：股东可现场查阅股东名册信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2586236767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586236767?lang=zh_cn&edition=full","pubTime":"2025-11-26 15:21","pubTimestamp":1764141682,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康11月26日在投资者关系平台上答复投资者关心的问题。为了保障股东的查阅权并遵循上市公司信息保密性及公平性原则，如您确需查询公司其他时点的股东名册信息，您可携带持股证明及身份证件至公司进行现场查阅，公司将在核实股东身份后予以提供。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600017364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2586420552","title":"昂利康最新公告：拟定增募资不超过11.6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586420552?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:00","pubTimestamp":1764072033,"startTime":"0","endTime":"0","summary":"昂利康(002940.SZ)公告称，拟定增募资不超过11.6亿元，用于创新药研发及产业化项目。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500034188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"1159591875","title":"昂利康药业计划通过A股定增筹集12亿元以支持项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1159591875","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159591875?lang=zh_cn&edition=full","pubTime":"2025-11-25 19:59","pubTimestamp":1764071949,"startTime":"0","endTime":"0","summary":"昂利康药业计划通过A股定增筹集12亿元，以资助相关项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2585604934","title":"昂利康（002940）披露2025年第二次临时股东大会决议公告，11月24日股价上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585604934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585604934?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:13","pubTimestamp":1763993605,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，昂利康报收于39.05元，较前一交易日上涨1.8%，最新总市值为78.77亿元。近日，浙江昂利康制药股份有限公司发布2025年第二次临时股东大会决议公告。公告显示，公司于2025年11月24日召开2025年第二次临时股东大会，会议审议通过了《关于修订<公司章程>的议案》等11项议案。中小投资者对各项议案的同意率均超过92%。浙江天册律师事务所对本次会议出具了法律意见书，认为会议程序合法、表决结果有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2584564939","title":"昂利康(002940.SZ)：化学原料药布比卡因上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584564939","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584564939?lang=zh_cn&edition=full","pubTime":"2025-11-17 17:42","pubTimestamp":1763372525,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)公告，公司收到国家药品监督管理局签发的《化学原料药上市申请批准通知书》，化学原料药名称为布比卡因。布比卡因制剂临床上主要用于局部麻醉和术后镇痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)：化学原料药布比卡因上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2584643329","title":"11月17日昂利康跌7.60%，富国天盛灵活配置基金基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584643329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584643329?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:33","pubTimestamp":1763368433,"startTime":"0","endTime":"0","summary":"证券之星消息，11月17日昂利康跌7.60%，收盘报43.43元，换手率13.58%，成交量25.16万手，成交额11.12亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为富国基金的富国天盛灵活配置基金。富国天盛灵活配置基金目前规模为6.7亿元，最新净值1.343，较上一交易日下跌0.59%，近一年上涨38.45%。该公募基金现任基金经理为肖威兵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700020912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239"],"gpt_icon":0},{"id":"2583482575","title":"11月14日昂利康涨5.52%，富国天盛灵活配置基金基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583482575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583482575?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:35","pubTimestamp":1763109359,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日昂利康涨5.52%，收盘报47.0元，换手率17.73%，成交量32.86万手，成交额15.12亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为富国基金的富国天盛灵活配置基金。富国天盛灵活配置基金目前规模为6.7亿元，最新净值1.351，较上一交易日上涨2.5%，近一年上涨36.19%。该公募基金现任基金经理为肖威兵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400025852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002940"],"gpt_icon":0},{"id":"2582351191","title":"昂利康(002940.SZ)：多索茶碱片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2582351191","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582351191?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:03","pubTimestamp":1762851791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昂利康(002940.SZ)发布公告，近日，公司收到国家药品监督管理局(以下简称“国家药监局”)签发的多索茶碱片(0.2g、0.4g)《药品补充申请批准通知书》，该药品已通过仿制药质量和疗效一致性评价。多索茶碱片适用于支气管哮喘、喘息性慢性支气管炎及其他支气管痉挛引起的呼吸困难。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昂利康(002940.SZ)：多索茶碱片通过仿制药一致性评价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002940","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768391190801,"stockEarnings":[{"period":"1week","weight":0.0618},{"period":"1month","weight":0.0792},{"period":"3month","weight":-0.1014},{"period":"6month","weight":-0.1789},{"period":"1year","weight":1.7771},{"period":"ytd","weight":0.1017}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江昂利康制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"28533人(较上一季度增加54.58%)","perCapita":"6493股","listingDate":"2018-10-23","address":"浙江省绍兴市嵊州市嵊州大道北1000号","registeredCapital":"20172万元","survey":" 浙江昂利康制药股份有限公司的主营业务是从事化学原料药及制剂的研发、生产和销售。公司的主要产品是化学原料药及制剂。","listedPrice":23.07},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昂利康,002940,昂利康股票,昂利康股票老虎,昂利康股票老虎国际,昂利康行情,昂利康股票行情,昂利康股价,昂利康股市,昂利康股票价格,昂利康股票交易,昂利康股票购买,昂利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昂利康(002940)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昂利康(002940)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}